Recent research indicates that the diabetes medication metformin may extend the lives of older women, potentially increasing their chances of reaching the age of 90. This study, conducted by scientists in the US and Germany, highlights metformin’s various anti-aging properties that could contribute to improved longevity.
The research analyzed data from a long-term study of postmenopausal women, focusing on 438 participants. Half of the participants received metformin for managing type 2 diabetes, while the other half were prescribed a different diabetes medication, sulfonylurea. The findings revealed that those in the metformin group exhibited a 30 percent lower risk of dying before reaching 90 compared to their counterparts on sulfonylurea.
In their published paper in the Journal of Gerontology: Medical Sciences, the researchers noted, “Metformin has been shown to target multiple pathways of aging and therefore has been postulated as a drug that may extend human longevity.” This highlights the growing interest in metformin not just as a treatment for diabetes, but as a potential means to enhance lifespan.
Metformin has been used for decades and is classified as a gerotherapeutic, a category of drugs that may slow down aging processes within the body. Studies suggest that it can limit DNA damage and promote gene activity associated with longevity. Moreover, metformin has demonstrated the ability to reduce wear and tear in the brain and has even been associated with a decreased risk of long COVID.
Despite these promising findings, researchers caution that this study does not establish a direct cause-and-effect relationship. Unlike randomized controlled trials (RCTs), which can definitively determine the efficacy of a treatment, this study’s participants were not randomly assigned to their respective medications. Instead, they followed the guidance of healthcare professionals in their treatment choices. Additionally, the study lacked a placebo group, and the overall sample size was relatively modest.
Nevertheless, the study boasts a significant strength: the average follow-up period lasted between 14 to 15 years. This extended timeframe is crucial for understanding the long-term impact of interventions on lifespan, as noted by the researchers. They stated, “A key advantage of our analysis was the long follow-up period after treatment initiation enabled by examination of a cohort with extensive follow-up from midlife to ages 90 and older, which is not feasible in typical randomized controlled trials.”
Looking ahead, the researchers suggest that further RCTs could provide deeper insights into these findings. As populations worldwide continue to age, understanding how to maintain health and mitigate damage as we grow older remains a priority for the scientific community.
The researchers also referenced the geroscience hypothesis, which proposes that biological aging can be modified, potentially delaying or preventing age-related diseases. They emphasized that a primary goal of geroscience is to identify new therapeutic and preventive interventions that could slow biological aging.
As interest in the anti-aging benefits of medications like metformin grows, further investigations will be crucial in validating these findings. The implications of such research could significantly impact public health strategies aimed at improving quality of life for aging populations.
